car t biomarker

1
CAR T Immunotherapy
www.creative-biolabs.com/car-t
2
CAR T paper
The original CAR-T or the first-generation CAR
consists of the intracellular domain from the CD3
?- chain and the primary transmitter of signals
from endogenous TCRs, which showed success in
pre-clinical trials and entered Phase I clinical
trials in ovarian cancer, neuroblastoma and
various types of leukemia and lymphoma. Although
the anti-tumor activity was limited due to
insufficient activation, persistence and homing
to the cancer tissue, some significant effects
indeed existed in patients with B-cell lymphoma
treated with a-CD20-CD3 ? CAR-modified T cells
and some neuroblastoma treated with ScFv-CD3 ?
CAR-Ts. Here we select some of the classical
literature in the field of chimeric antigen
receptor technology. It is hoped that these
reviews and research articles will help you to
understand CAR technology quickly and keep up
with the cutting edge development of this area.
3
car t biomarker
In a broad sense, cancer biomarker is an
indicative of the presence of cancer in the body
or a molecule secreted by a tumor or a specific
response of the body to the presence of
cancer. It is usually identifiable or measurable
in the blood, urine or other convenient body
fluids by PCR, ELISA, and other conventional
immune assays. In this sense, biomarkers can be
categorized into genetic, epigenetic, proteomic,
glycomic, and imaging biomarkers for cancer
diagnosis, prognosis, and epidemiology. In a
narrow sense of cancer biomarker, it is limited
to proteins the most used to challenge in the
clinical applications, especially in the CAR-T
therapy. Specifically, a cancer biomarker of
the CAR-T provides the most prominent signal of
cancer cells for distinguishing from normal cells
and the most effective target for immune
recognition and destruction.
4
Biomarker Identification Selection High
Affinity ScFv Generation CAR Design
Construction Virus Packaging CAR Gene
Delivery CAR-T In Vitro Assay CAR-T Preclinical
In Vivo Assay CAR-T Clinical Trail
7
5
(No Transcript)
6
THANKS
!